This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Policy

LUX-Lung 3 & 6 clinical data
GIOTRIF® significantly improved PFS in patients with stable brain metastases at time of enrolment and common mutations versus chemotherapy1

LUX-Lung 3 and 6: combined PFS analysis in patients with brain metastases 

LUX-Lung 3 and 6: combined PFS analysis in patients with brain metastases 

  • Significant PFS in patients with stable brain metastases at the time of enrolment and common mutations versus chemotherapy (HR=0.50; P=0.0297)1
  • GIOTRIF® significantly improved tumour response rates in patients with and without brain metastases and common EGFR mutations versus chemotherapy1
  • Median time to CNS progression was longer with GIOTRIF® versus with chemotherapy (LUX-Lung 3: 15.2 months [95% CI: 7.7–29.0] and 5.7 months [95% CI: 2.6–8.2]; LUX-Lung 6: 15.2 months [95% CI: 3.8–23.7] and 7.3 months [95% CI: 3.7–10.9])1

EGFR= epidermal growth factor receptor; PFS= progression-free survival; HR=hazard ratio; CI=confidence interval

Watch Vera Hirsh's opinion on the treatment of brain metastases!

You may be interested in: 

First-Line Afatinib versus Chemotherapy in Patients with Non–Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases

Schuler et al., Journal of Thoracic Oncology, Volume 11, Issue 3, March 2016, Pages 380-390

Download the publication!

Optimizing outcomes in EGFR mutation-positive NSCLC: which tyrosine kinase inhibitor and when?

Nicolas Girard, Future Oncology, 2018

 

Download the publication!

EGFR M+=epidermal growth factor receptor mutation positive; NSCLC=non-small cell lung cancer

Is this information compelling to you?

Request contact
from Boehringer Ingelheim

References

  1. Schuler M et al. J Thorac Oncol. 2016;11(3):380-390.
  2. Hoffknecht et al. J Thorac Oncol. 2015;10(1):156-163.
  3. Yang JC et al. Lancet Oncol. 2015;16:830-838.
  4. Sequist LV et al. J Clin Oncol. 2013;31(27):3327-3334
  5. Park K et al. Lancet Oncol. 2016;17(5):577-589.
  6. Hirsch V et al. Poster #369 presented at: American Society of Clinical Oncology (ASCO) Annual Meeting; Chicago, IL, USA; 3-7 June 2016.
  7. Yang JCH et al. Ann Oncol. 2016;27(11):2103-2110.
  1. Sequist LV et al. J Clin Oncol. 2013;31(27):3327-3334.

  2. Wu YL et al. Lancet Oncol. 2014;15(2):213-222.

  3. Yang JC et al. Lancet Oncol. 2015;16(2):141-151.

  4. Park K et al. Lancet Oncol. 2016;17(5):577-589.

  5. Soria JC et al. Lancet Oncol. 2015;16(8):897-907.

  6. Solca F et al. J Pharmacol Exp Ther. 2012;343(2):342-350.

  7. Yang JC et al. J Clin Oncol. 2013;31(27):3342-3350.

  8. Hirsch V et al. Poster #369 presented at: American Society of Clinical Oncology (ASCO) Annual Meeting; Chicago, IL, USA; 3-7 June 2016.

  9. Yang JCH et al. Ann Oncol. 2016;27(11):2103-2110.

  10. Schuler M et al. J Thorac Oncol. 2016;11(3):380-390.

  11. Paz-Arez L et al. Ann Oncol. 2017; doi: 10.1093/annonc/mdw611.

  12. GIOTRIF® (afatinib) Summary of Product Characteristics, 2016.

Report an adverse event

If you wish to report an adverse event (AE) after treatment with one of our products, please select your site from the link below. This will allow reporting of AEs in line with the reporting procedure effective in your country for reporting.

Boehringer Ingelheim local websites
Back to top